Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

BACKGROUND: Retinopathy is a common adverse event with mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors. Little is known about the pathophysiology of MEK inhibitor-associated retinopathy (MEKAR). Since MEKAR has many similarities to central serous chorioretinopathy (CSCR), th...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Andrew E. C., Hopkins, Ashley M., Rowland, Andrew, Kichenadasse, Ganessan, Smith, Justine R., Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406936/
https://www.ncbi.nlm.nih.gov/pubmed/32821295
http://dx.doi.org/10.1177/1758835920944359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406936/
https://www.ncbi.nlm.nih.gov/pubmed/32821295
http://dx.doi.org/10.1177/1758835920944359

Ejemplares similares